Directorio

We are doing this study to find out if a drug called satralizumab (the study drug) is a safe and effective option for people with autoimmune encephalitis.

We are doing this study to collect information about the speeds of eye and head movements in healthy children and young adults. This information will help us establish normal values related to these movement speeds and patterns. If we have a measure of what is normal, this will help us determine the severity of symptoms or injury for people who are treated for concussions.

Everyone who joins this study will take a medicine called ribociclib by mouth once a day for 21 days, then have a 7-day break. This makes a 28-day cycle. They will also take hormone therapy (endocrine therapy) every day. This treatment will last for about 3 years (around 39 cycles). After finishing treatment or stopping early, patients will have a visit called End of Treatment and then a safety check 30 days later. After that, doctors will keep track of their health and survival for a long time—up to 4 years after the last person starts treatment.

We are doing this study to compare two commonly used treatment choices for early-stage breast cancer in premenopausal women. We want to know if either option is a better choice than the other.

We are doing this study to find out if a blood test for circulating tumor DNA (ctDNA) can provide information that might help doctors figure out the most appropriate therapy for patients with colon cancer after they have surgery.

We are doing this study to find out if an investigational drug called apalutamide (the study drug) is a safe and effective treatment for your form of cancer. We want to know how well people respond to the usual therapy (hormone therapy and radiation) in combination with the study drug compared to the usual therapy on its own.

We are doing this study to find out if adding radiation therapy has any positive benefit when it is added to the usual treatment regimen for this form of cancer.